title: Supraventricular tachycardia in neonates: antiarrhythmic drug choice dilemma.
abstract: Supraventricular tachycardia (SVT), being atrioventricular re-entry the underlying mechanism, is the most frequent tachyarrhythmia requiring a medical treatment in infants with no cardiac disease. The acute treatment of a single episode of SVT has generally an excellent prognosis. An antiarrhythmic prophylaxis of SVT recurrences is usually recommended during the first year of life. Although many efficient drugs are available for the SVT treatment, a careful risk-benefit analysis of each single case should suggest the correct drug choice.
authors.affiliation: Division of Paediatric Cardiology, G. Brotzu Hospital, Cagliari, Italy.
authors.forename: Maria Cristina
authors.initials: MC
authors.lastname: Tavera
authors.forename: Pier Paolo
authors.initials: PP
authors.lastname: Bassareo
authors.forename: Paola
authors.initials: P
authors.lastname: Neroni
authors.forename: Chiara
authors.initials: C
authors.lastname: Follese
authors.forename: Donatella
authors.initials: D
authors.lastname: Manca
authors.forename: Sabrina
authors.initials: S
authors.lastname: Montis
authors.forename: Roberto
authors.initials: R
authors.lastname: Tumbarello
mesh_terms: D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use*; D018890:Chemoprevention / Q000379:methods; D002755:Choice Behavior / Q000502:physiology; D003657:Decision Making / Q000502:physiology; D006801:Humans; D007231:Infant, Newborn; D007232:Infant, Newborn, Diseases / Q000188:drug therapy* / Q000517:prevention & control; D055502:Secondary Prevention; D013617:Tachycardia, Supraventricular / Q000188:drug therapy* / Q000517:prevention & control
chemical_list: D000889:Anti-Arrhythmia Agents